Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 100 movers: AstraZeneca in the black; Reckitt tumbles
(Sharecast News) - London's FTSE 100 was up 0.3% at 8,309.79 in afternoon trade on Monday. AstraZeneca was in the black as it hailed positive high-level results from a clinical trial of its Calquence treatment for adults with chronic lymphocytic leukaemia (CLL).
Entain fell as it said that BetMGM - its sports betting and iGaming operator in the US - surpassed the $1bn mark for revenues in the first half, but still made a loss as a result of heavy investments during the period.
Reckitt Benckiser was under the cosh amid concerns about potential litigation, after a US jury found on Friday that infant formula by Abbott Laboratories had caused a girl to develop a dangerous bowel disease.
Abbott was ordered to pay $495m in damages. This consisted of $95m compensatory damages and $400m punitive.
Dan Coatsworth, investment analyst at AJ Bell, said: "Reckitt's shares have been severely depressed since March as the market worries about the scale of any potential liabilities if the company loses legal battles around the safety of its baby formula.
"A US court case has already awarded $60 million in damages to a mother who said her baby died after consuming Reckitt's Enfamil baby formula. Several hundred similar claims have been in filed in US courts targeting Reckitt and Abbott.
"The more setbacks for either baby formula maker, the more complicated it becomes for Reckitt to sell its nutrition arm. Reckitt last week indicated it might be up for sale, saying it was considering all options for the business.
"Any potential buyer could be put off by the possibility of liabilities from the court cases, meaning the pressure is growing for Reckitt to find a way to ringfence a large amount of money in case it loses big time in the court battles."
BA and Iberia owner IAG flew lower ahead of half-year results at the end of the week.
FTSE 100 - Risers
Airtel Africa (AAF) 114.40p 4.19% SEGRO (SGRO) 918.60p 2.98% JD Sports Fashion (JD.) 126.95p 2.92% Prudential (PRU) 700.60p 2.28% NATWEST GROUP (NWG) 369.90p 2.21% AstraZeneca (AZN) 12,430.00p 1.92% 3i Group (III) 3,086.00p 1.92% M&G (MNG) 211.30p 1.88% Lloyds Banking Group (LLOY) 61.44p 1.76% Persimmon (PSN) 1,587.00p 1.73%
FTSE 100 - Fallers
Entain (ENT) 586.80p -9.58% Reckitt Benckiser Group (RKT) 4,065.00p -9.38% International Consolidated Airlines Group SA (CDI) (IAG) 164.50p -1.59% Fresnillo (FRES) 570.00p -1.55% Flutter Entertainment (DI) (FLTR) 15,150.00p -1.30% Anglo American (AAL) 2,357.00p -1.26% Burberry Group (BRBY) 738.00p -1.23% Diageo (DGE) 2,542.50p -0.90% Glencore (GLEN) 429.60p -0.87% Beazley (BEZ) 664.00p -0.67%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
